Enanta Pharmaceuticals Inc
$ 13.52
-2.10%
11 Aug - close price
- Market Cap 400,409,000 USD
- Current Price $ 13.52
- High / Low $ 13.82 / 12.71
- Stock P/E N/A
- Book Value 4.01
- EPS -2.60
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.59 %
- 52 Week High 17.15
- 52 Week Low 6.60
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$21.17
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-10 | 2026-05-11 | 2026-02-09 | 2025-11-17 | 2025-08-11 | 2025-05-12 | 2025-02-10 | 2024-11-25 | 2024-08-05 | 2024-05-06 | 2024-02-07 | 2023-11-20 |
| Reported EPS | -0.67 | -0.45 | -0.42 | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 | -1.58 | -1.33 |
| Estimated EPS | -0.37 | -0.57 | -0.88 | -1.01 | -0.88 | -1.14 | -1.35 | -0.92 | -1.41 | -1.4 | -1.23 | -2.21 |
| Surprise | -0.3 | 0.12 | 0.46 | 0.14 | 0.03 | 0.08 | 0.3 | -0.44 | 0.34 | -0.07 | -0.35 | 0.88 |
| Surprise Percentage | -81.0811% | 21.0526% | 52.2727% | 13.8614% | 3.4091% | 7.0175% | 22.2222% | -47.8261% | 24.1135% | -5% | -28.4553% | 39.819% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENTA
2026-08-11 00:44:04
Enanta Pharmaceuticals reported a net loss of $19.5 million for Q3 FY26, with revenue dropping 21% year-over-year to $14.4 million, missing analyst estimates. Despite financial setbacks, the company advanced its RSV pipeline, initiating the LOTUS pediatric trial and preparing for the RESOLVE adult trial. Enanta maintains a strong cash position of $211.5 million, providing financial runway into fiscal 2029.
2026-08-10 20:44:04
Enanta Pharmaceuticals (NASDAQ:ENTA) reported a quarterly loss of $0.67 per share, missing analyst estimates by $0.16. The biotechnology company also showed negative return on equity and net margin. Despite the earnings miss, the stock rose 0.3% during Monday trading, and institutional investors hold a significant portion of the company's shares.
2026-08-10 20:44:04
Enanta Pharmaceuticals reported a Q3 fiscal year loss of $19.5 million on revenue of $14.4 million, with $211.5 million in cash and marketable securities. The company expects current resources to fund operations into fiscal 2029 and highlighted progress in its virology and immunology programs, including a Phase 2b pediatric trial for zelicapavir and a Phase 1 readout for EDP-978 in Q4 2026.
2026-08-10 20:44:04
Enanta Pharmaceuticals reported third-quarter results that fell short of analyst expectations, with adjusted earnings per share of -$0.67 and revenue of $14.4 million, missing estimates of -$0.50 and $17.4 million, respectively. This underperformance was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with topline data for a Phase 2b pediatric trial expected in 2027 and a registrational Phase 2b/3 trial for high-risk adults on track for Q4 2026.
2026-08-10 20:44:04
Enanta Pharmaceuticals reported a 21.6% decline in fiscal Q3 2026 revenue to $14.4 million due to lower MAVYRET/MAVIRET royalties. Despite narrowed operating losses from reduced clinical trial spending, the net loss widened to $19.5 million because of increased royalty-related interest expenses. The company holds $211.5 million in cash and marketable securities, expected to fund operations through fiscal 2029, and is focusing on key clinical trials and managing patent litigation risks.
2026-08-10 20:44:03
Enanta Pharmaceuticals (ENTA) reported a Q3 loss of $0.67 per share, significantly missing the Zacks Consensus Estimate of a $0.37 loss, and its revenues of $14.36 million also fell short of expectations. Despite exceeding EPS estimates three times in the last four quarters, the company's shares have declined 12.7% year-to-date. Investors are now looking to management's commentary and future earnings outlook, with the stock currently holding a Zacks Rank #3 (Hold).
